Mobile App

Google Play Apple Store
Solving the Puzzle: Diagnostic and Treatment Innovations in Myelofibrosis - Updated 7/1/2024
AMA/ABS/ANCC Activity - Lecture Library Slide Set
Clinical Viewpoints MF includes a curriculum that highlights the very latest clinical data in myelofibrosis. Slides are developed and updated throughout the year by leading MF expert physicians. All content is reviewed and approved by the Clinical Viewpoints MF Planning Committee.

Myelofibrosis is a myeloproliferative neoplasm characterized by clonal proliferation of myeloid cells, bone marrow fibrosis and cytopenias, extramedullary hematopoiesis and hepatosplenomegaly, increased pro-inflammatory cytokine production, and systemic symptoms. Patients with MF also have a propensity toward leukemic transformation. Allogeneic hematopoietic stem cell transplantation (aHCT) is the only curative therapy for patients with MF; however, transplant-related morbidity and mortality precludes this option for the majority of patients. In the last decade, four targeted therapies have been approved for the treatment of MF, all JAK2 inhibitors, ruxolitinib, fedratinib, pacritinib, and momelotinib. Moreover, there are a number of novel therapeutic targets with drug candidates in late-stage (phase II or III) clinical development for the treatment of MF. This case-based slide kit discusses the pathophysiology, burden diagnosis, current and future treatment strategies, risk stratification, adverse events associated with therapies as well as the importance of patient-centered care.

Updated information is noted on the slide in the upper right hand corner. Please note that participants who have previously claimed credit for this activity should not claim duplicate credit based on the updates.
Review the activity and claim AMA/ABS/ANCC credit/contact hour after completion of a brief pretest and posttest/evaluation.

John Mascarenhas, MD John Mascarenhas, MD
Professor of Medicine
Icahn School of Medicine at Mount Sinai
Director of the Center of Excellence
for Blood Cancers and Myeloid Disorders
New York, New York

Supported by an independent educational grant from
CTI Biopharma Corp., a Sobi company

Launch Date: June 14, 2024
Release Date: June 14, 2024
Expiration Date: May 31, 2025

Mini Module
LectureLibrary_Myelofibrosis _2024(1730x162).png


Change Settings